Jacques Donnez, Christian Becker, Hugh Taylor, Francisco Carmona Herrera, Olivier Donnez, Andrew Horne, Maciej Paszkowski, Felice Petraglia, Stefan P Renner, Amisha Patel, Mitra Boolell, Elke Bestel, Marie-Madeleine Dolmans
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone acetate [NETA]) demonstrate better efficacy than placebo in the management of endometriosis-related dysmenorrhea and non-menstrual pelvic pain? SUMMARY ANSWER: Combining 200 mg linzagolix with ABT was found to significantly reduce dysmenorrhea and non-menstrual pelvic pain at 3 months of therapy, while a daily dose of 75 mg linzagolix yielded a significant decrease only in dysmenorrhea at 3 months...
April 22, 2024: Human Reproduction